259 related articles for article (PubMed ID: 20688626)
21. Three novel mutations of the PHEX gene in three Chinese families with X-linked dominant hypophosphatemic rickets.
Xia W; Meng X; Jiang Y; Li M; Xing X; Pang L; Wang O; Pei Y; Yu LY; Sun Y; Hu Y; Zhou X
Calcif Tissue Int; 2007 Dec; 81(6):415-20. PubMed ID: 18046499
[TBL] [Abstract][Full Text] [Related]
22. [Medical treatment of children with hypophosphataemic rickets].
Rahbek ET; Nielsen LH; Beck-Nielsen SS; Christesen HT
Ugeskr Laeger; 2014 Feb; 176(9A):V10130629. PubMed ID: 25350412
[TBL] [Abstract][Full Text] [Related]
23. A novel c.2179T>C mutation blocked the intracellular transport of PHEX protein and caused X-linked hypophosphatemic rickets in a Chinese family.
Li B; Wang X; Hao X; Liu Y; Wang Y; Shan C; Ao X; Liu Y; Bao H; Li P
Mol Genet Genomic Med; 2020 Aug; 8(8):e1262. PubMed ID: 32511895
[TBL] [Abstract][Full Text] [Related]
24. Genetic analysis of three families with X-linked dominant hypophosphatemic rickets.
Lin X; Zhu Y; Luo J; Huang J
J Pediatr Endocrinol Metab; 2018 Jul; 31(7):789-797. PubMed ID: 29858904
[TBL] [Abstract][Full Text] [Related]
25. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status.
Carpenter TO; Insogna KL; Zhang JH; Ellis B; Nieman S; Simpson C; Olear E; Gundberg CM
J Clin Endocrinol Metab; 2010 Nov; 95(11):E352-7. PubMed ID: 20685863
[TBL] [Abstract][Full Text] [Related]
26. [Genetic and clinical analysis of X-linked hypophosphatemic rickets].
Wei LY; Gong CX; Cao BY; Li XQ; Liang XJ; Li WJ; Wu D; Liu M; Su C; Chen JJ
Zhonghua Er Ke Za Zhi; 2021 Aug; 59(8):678-683. PubMed ID: 34333921
[No Abstract] [Full Text] [Related]
27. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations.
Imel EA; DiMeglio LA; Hui SL; Carpenter TO; Econs MJ
J Clin Endocrinol Metab; 2010 Apr; 95(4):1846-50. PubMed ID: 20157195
[TBL] [Abstract][Full Text] [Related]
28. Bone Deformities and Kidney Failure: Coincidence of PHEX-Related Hypophosphatemic Rickets and m.3243A>G Mitochondrial Disease.
Nielsen SR; Hansen SG; Bistrup C; Brusgaard K; Frederiksen AL
Calcif Tissue Int; 2022 Dec; 111(6):641-645. PubMed ID: 35916905
[TBL] [Abstract][Full Text] [Related]
29. Mutational survey of the PHEX gene in patients with X-linked hypophosphatemic rickets.
Ichikawa S; Traxler EA; Estwick SA; Curry LR; Johnson ML; Sorenson AH; Imel EA; Econs MJ
Bone; 2008 Oct; 43(4):663-6. PubMed ID: 18625346
[TBL] [Abstract][Full Text] [Related]
30. Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population.
Rodríguez-Rubio E; Gil-Peña H; Chocron S; Madariaga L; de la Cerda-Ojeda F; Fernández-Fernández M; de Lucas-Collantes C; Gil M; Luis-Yanes MI; Vergara I; González-Rodríguez JD; Ferrando S; Antón-Gamero M; Carrasco Hidalgo-Barquero M; Fernández-Escribano A; Fernández-Maseda MÁ; Espinosa L; Oliet A; Vicente A; Ariceta G; Santos F;
Orphanet J Rare Dis; 2021 Feb; 16(1):104. PubMed ID: 33639975
[TBL] [Abstract][Full Text] [Related]
31. Rickets guidance: part II-management.
Haffner D; Leifheit-Nestler M; Grund A; Schnabel D
Pediatr Nephrol; 2022 Oct; 37(10):2289-2302. PubMed ID: 35352187
[TBL] [Abstract][Full Text] [Related]
32. High iFGF23 level despite hypophosphatemia is one of the clinical indicators to make diagnosis of XLH.
Igaki JM; Yamada M; Yamazaki Y; Koto S; Izawa M; Ariyasu D; Suzuki E; Hasegawa H; Hasegawa Y
Endocr J; 2011; 58(8):647-55. PubMed ID: 21597229
[TBL] [Abstract][Full Text] [Related]
33. Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment.
Quinlan C; Guegan K; Offiah A; Neill RO; Hiorns MP; Ellard S; Bockenhauer D; Hoff WV; Waters AM
Pediatr Nephrol; 2012 Apr; 27(4):581-8. PubMed ID: 22101457
[TBL] [Abstract][Full Text] [Related]
34. Phosphate homeostasis and genetic mutations of familial hypophosphatemic rickets.
Razali NN; Hwu TT; Thilakavathy K
J Pediatr Endocrinol Metab; 2015 Sep; 28(9-10):1009-17. PubMed ID: 25894638
[TBL] [Abstract][Full Text] [Related]
35. Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report.
Takashi Y; Toyokawa K; Oda N; Muta Y; Yokomizo H; Fukumoto S; Kawanami D
Front Endocrinol (Lausanne); 2022; 13():1004624. PubMed ID: 36531500
[TBL] [Abstract][Full Text] [Related]
36. PHEX gene mutation in a Chinese family with six cases of X-linked hypophosphatemic rickets.
Yang L; Yang J; Huang X
J Pediatr Endocrinol Metab; 2013; 26(11-12):1179-83. PubMed ID: 23813354
[TBL] [Abstract][Full Text] [Related]
37. Management of X-linked hypophosphatemia in adults.
Lecoq AL; Brandi ML; Linglart A; Kamenický P
Metabolism; 2020 Feb; 103S():154049. PubMed ID: 31863781
[TBL] [Abstract][Full Text] [Related]
38. Treatment of hypophosphataemic rickets in children remains a challenge.
Nielsen LH; Rahbek ET; Beck-Nielsen SS; Christesen HT
Dan Med J; 2014 Jul; 61(7):A4874. PubMed ID: 25123121
[TBL] [Abstract][Full Text] [Related]
39. Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets.
Mäkitie O; Kooh SW; Sochett E
Clin Endocrinol (Oxf); 2003 Feb; 58(2):163-8. PubMed ID: 12580931
[TBL] [Abstract][Full Text] [Related]
40. Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
Kuczera P; Adamczak M; Wiecek A
Clin Endocrinol (Oxf); 2014 Apr; 80(4):607-12. PubMed ID: 24111496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
